title: Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up.
abstract: OBJECTIVE
  To analyze the rate and baseline prognostic factors of disability measured by the modified HAQ (MHAQ), in a series of patients with early rheumatoid arthritis (RA) after two years of therapy with a structured algorithm using disease-modifying anti-rheumatic drugs (DMARDs).
  
  
  METHODS
  One hundred and five patients (81% female) with early RA (disease duration <2 years) treated with the same therapeutic protocol using gold salts and methotrexate in a step-up strategy, together with methylprednisolone (4 mg/day), were followed up for two years. The outcome was the absence of disability (MHAQ=0) after two years of DMARD therapy. Clinical, biological, immunogenetic and radiographic data (Larsen score) were analyzed at study entry and at 12 and 24 months of follow-up.
  
  
  RESULTS
  The MHAQ decreased significantly at 6 months after initiation of DMARD therapy and the reduction was maintained at 24 months (mean+/-SD: 0.97+/-0.56 at baseline, 0.51+/- 0.57 at month 6 and 0.45+/-0.5 at month 24). No disability (MHAQ=0) was observed in 26.6% of patients after two years of follow-up. Age, MHAQ>0.5, DAS28>5.1, VAS pain, positive rheumatoid factor and ESR at baseline were associated with disability in the univariate analysis. In the logistic regression analysis, only age (OR: 1.058, 95%CI 1.017; 1.101 p<0.006), rheumatoid factor status (OR: 3.772 95%CI 1.204; 11.813, p<0.02) and MHAQ>0.5 (OR:4.023, 95%CI 1.373; 11.783, p<0.02) were associated with disability (MHAQ>0) at two years.
  
  
  CONCLUSIONS
  In a series of early RA patients treated with a structured algorithm using DMARDs and very low doses of glucocorticoids, no disability was observed in a quarter of patients after two years. Age, rheumatoid factor positivity and MHAQ>0.5 were independent predictors of disability at two years.
authors.affiliation: Arthritis Unit. Rheumatology Service, IDIBAPS, Hospital Clínic of Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Graell
authors.forename: I
authors.initials: I
authors.lastname: Vazquez
authors.forename: M
authors.initials: M
authors.lastname: Larrosa
authors.forename: J R
authors.initials: JR
authors.lastname: Rodríguez-Cros
authors.forename: M V
authors.initials: MV
authors.lastname: Hernández
authors.forename: J
authors.initials: J
authors.lastname: Gratacós
authors.forename: A
authors.initials: A
authors.lastname: Gómez
authors.forename: J D
authors.initials: JD
authors.lastname: Cañete
authors.forename: J A
authors.initials: JA
authors.lastname: Gómez-Puerta
authors.forename: R
authors.initials: R
authors.lastname: Sanmartí
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D004185:Disability Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006052:Gold Sodium Thiomalate / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D012217:Rheumatoid Factor / Q000097:blood; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D018501:Antirheumatic Agents; D006052:Gold Sodium Thiomalate; D012217:Rheumatoid Factor; D008727:Methotrexate